antitumor activity of Klebsiella 03 lipopolysaccharide (K03 LPS) isolated from the culture supernatant against S180 sarcoma, Ehrlich carcinoma, MM2 mammary carcinoma and Meth A fibrosarcoma in mice was investigated. K03 LPS significantly prolonged the lifespan of S180-bearing ddY mice and MM2 bearing C3H/He mice by intraperitoneal pre or postmedication at doses ranging from 0.1 to 1.0 mg/kg.
Abstract-The
antitumor activity of Klebsiella 03 lipopolysaccharide (K03 LPS) isolated from the culture supernatant against S180 sarcoma, Ehrlich carcinoma, MM2 mammary carcinoma and Meth A fibrosarcoma in mice was investigated. K03 LPS significantly prolonged the lifespan of S180-bearing ddY mice and MM2 bearing C3H/He mice by intraperitoneal pre or postmedication at doses ranging from 0.1 to 1.0 mg/kg.
The LPS also inhibited the growth of subcutaneously inoculated Ehrlich carcinoma in ddY mice and Meth A sarcoma in BALB/c mice by intraperitoneal, intravenous or intratumoral administration.
The intratumoral injection of K03 LPS was most effective and results by the intravenous and the intraperitoneal administrations followed in effectiveness, but the administration through the subcutaneous route was hardly effective. Thus, K03 LPS was shown to have antitumor activity on both allogeneic tumors and syngeneic tumors. It was also indicated in this study that the lifeprolonging effect of K03 LPS on S180 ascites type tumor-bearing mice was significantly minimized by pretreatment of cyclophosphamide and that the LPS did not influence the cell viability of HeLa cells, Ehrlich cells and MM2 cells in vitro. These results suggest that the antitumor activity of K03 LPS is provided by host-mediated actions.
It has been indicated that lipopolysac charides (LPSs) from various gram-negative bacteria show antitumor activity in animals, and the activity is attributable to their host mediated immunostimularoty action (1-3 Table 1 and Fig. 1 , respec tively (9). Other agents used were LPS from Escherichia coli 055:B5 (E055 LPS, Difco) and cyclophosphamide (CPA, Shionogi).
Antitumor activities in mice: To determine the antitumor activities against ascites type tumors, mice were inoculated with tumor cells (allogeneic tumor system: 1 X 106 S180 cells/ddY mouse, syngeneic tumor system: 5 X 105 MM2 cells/C3H/He mouse) on day 0 and were medicated intraperitoneally (i.p.) according to the treatment schedule indicated in the tables. Sixty days after the cell inocu lation, survivors were killed and autopsied. For solid type tumors, mice were inoculated subcutaneously (s.c.) at the left inguinal region with tumor cells (allogeneic tumor system: 5x106 Ehrlich cells/ddY mouse, syngeneic tumor system: 2x105 Meth A cells/BALB/c mouse) on day 0 and were medicated i.p., intravenously (i.v.) at the tail, s.c. at the right inguinal region or intra tumorally (i.t.) according to the treatment schedule indicated in the tables. Thirty-eight days after inoculation of Ehrlich cells or twenty-four days after inoculation of Meth A cells, the tumors were removed and weighed.
Single dosage was determined from the LD50 values (15.2 mg/kg i.p., 7.9 mg/kg i.v.) in SMA mice which are a sensitive strain to the LPS.
Assay of direct cytotoxic activity against tumor cells: HeLa cells, Ehrlich cells and MM2 cells were used in this study. The activity of K03 LPS against HeLa cells was evaluated using the colony-forming method. The cells (1 X104/2 ml) plated on 35 mm plastic petri dishes were incubated with graded concen trations of the agent at 37°C in a humidified 5% C02 incubator for 48 hr. The treated cells were washed with Hanks' solution and were further incubated for 48 hr. The colonies formed with 8-10 cells were fixed, stained with Crystal Violet, and then counted micro scopically. For Ehrlich cells and MM2 cells, a 2 ml aliquot of tumor cells (5x105/ml) prepared in RPMI 1640 medium supple mented with 10% fetal calf serum and 10 etM mercaptoethanol was placed in a 35 mm plastic dish and was added with graded concentrations of K03 LPS. The mixture was incubated at 37'C in a C02 incubator for 48 hr. The viable cells were assayed by a dye exclusion method with 0.2% Trypan Blue. Even when the LPS was given by a single intraperitoneal injection 7 days before tumor inoculation, a marked suppression of tumor growth was observed.
The effect of CPA on the antitumor activity of K03 LPS was also examined. CPA (40 mg/ kg) was injected i.p. once a day from day 6 to day 2 before the tumor inoculation. The lifeprolonging effect of K03 LPS in both medication schedules was cancelled or minimized by the pretreatment with CPA, while CPA alone hardly influenced the survival time of the mice bearing S180 ascites tumor (Table 2) . Table 2 . Antitumor activity of K03 LPS against S180 ascites type tumor and effect of CPA on the activity of K03 LPS Antitumor activity of K03 LPS against MM2 ascites type tumor: C3H/He mice were inoculated i.p. with 5X105 cells on day 0, and K03 LPS was administered i.p. once a day on days -7 to -2 as the premedication or on days +1 to +10 as the postmedication.
The agent showed a growth-inhibitory activity against MM2 ascites type tumor (Table 3) . The postmedication was more effective than the premedication, and all mice treated with 1.0 mg/kg of K03 LPS on days +1 to +10 survived for 60 days after the tumor in oculation. Antitumor activity of K03 LPS against Ehrlich solid type tumor: Mice were inocu lated s.c. with 5 x 106 cells and were given K03 LPS in the peritoneal cavity once a day for 10 days from 10 days after the cell inoculation or were given the agent i.v. by a single injection on day +10. As shown in Table 4 , the tumor growth in mice given K03 LPS i.p. or i.v. was significantly suppressed compared with that of the non-treated control. Particularly, three-tenths of the mice were cured by the treatment of 1.0 mg/kg of K03 LPS through each administration route, and the tumor growth in other mice was inhibited below 30% of the control.
Antitumor activity of K03 LPS against Meth A solid type tumor: Mice were inocu lated s.c. with 2 x 105 cells on day 0 and were given graded doses of K03 LPS through various routes according to the indicated schedules.
The antitumor activity of K03 LPS against Meth A solid type tumor was compared with that of E055 LPS (Table 5) . K03 LPS showed growth-inhibitory activity against the tumor to almost the same extent as that of E055 LPS. When K03 LPS was administered i.v. or i.t., the tumor growth was inhibited significantly, and the intratumoral administration of K03 LPS was especially effective, causing almost complete tumor regression in mice, even if given a single administration of 10 mg/kg on day +10. When administered i.p. or s.c., the tumor growth was mildly suppressed, but the tumor weight was not significantly different from that of the control. However, in every case of administration, the tumors weighing below about 30% of the control weight became necrotic with hemorrhage.
Direct cytotoxic activity of K03 LPS against tumor cells in vitro: Table 6 shows the results of experiments for the direct cytotoxic activity of K03 LPS against three target cell lines in the culture system. K03 LPS concen trations ranging from 10 to 100 ,cg/ml did not influence the colony-forming ability of HeLa cells treated with the agent for 48 hr. Moreover, significant decreases in the surviving fraction of Ehrlich cells and MM2 cells were not observed upon addition of 100 tag/ml of K03 LPS to the culture medium. These results indicate that K03 LPS has no direct cytotoxic activity against tumor cells i n vitro. Earlier, it was thought that the tumor regressing effect of LPSs depends on the intensity of the stimulation of the reticulo endothelial system, which provokes sub sequent antibody formation (3). LPSs generally consist of an 0-specific polysac charide moiety, a core moiety and a lipid A moiety. Our previous studies have revealed that LPSs including K03 LPS whose 0 specific polysaccharides consist of mannans showed a much stronger adjuvant activity than other LPSs such as E055 LPS and LPSs from Salmonella which don't possess mannans in their polysaccharide moiety (4-7). However, in this study, the antitumor activity of K03 LPS against Meth A fibrosar coma was indicated to be similar to that of E055 LPS by each administration route. Therefore, it may be difficult to attribute the antitumor activity of K03 LPS to its own adjuvant activities, and it seems that the antitumor activity of this LPS is based on the action of its lipid A moiety. We have reported that K03 LPS stimulates macrophages in vitro (11) and in vivo (12) and produces a large amount of interleukin 1 in macrophage cultures (13), interferon in mice (14, 15) and a cytotoxic factor (cytotoxin) in sera of BCG-infected mice (15). The properties of the cytotoxin were similar but not identical to those of the tumor necrosis factor (TNF) (15). TNF is produced in the sera of tumor bearing or BCG-infected mice by LPSs, and it is considered as a kind of monokine (16). In this study, tumors which were suppressed from growing by K03 LPS almost became necrotic with hemorrhage as in the cases of other LPSs (2, 17, 18) . This seems to suggest that TNF may also contribute to the antitumor effect of K03 LPS. From these results, it is thought that the antitumor effect of K03 LPS is provided by cell-mediated cytotoxicity, including the stimulation of macrophages.
